NeuroPace (NASDAQ:NPCE – Free Report) had its price objective decreased by Cantor Fitzgerald from $21.00 to $12.00 in a report released on Friday,Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the stock.
Other equities analysts have also recently issued reports about the stock. JPMorgan Chase & Co. cut shares of NeuroPace from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $20.00 to $9.00 in a research report on Friday. Guggenheim restated a “neutral” rating on shares of NeuroPace in a research report on Wednesday, July 29th. Raymond James Financial set a $21.00 price objective on NeuroPace in a report on Tuesday, September 15th. Weiss Ratings downgraded NeuroPace from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 2nd. Finally, KeyCorp lowered their target price on NeuroPace from $18.00 to $14.00 and set an “overweight” rating on the stock in a research note on Friday. Five research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, NeuroPace presently has an average rating of “Hold” and a consensus target price of $14.22.
View Our Latest Stock Report on NPCE
NeuroPace Stock Performance
Institutional Investors Weigh In On NeuroPace
Several institutional investors and hedge funds have recently bought and sold shares of NPCE. Legal & General Group Plc acquired a new stake in NeuroPace during the second quarter worth about $41,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of NeuroPace in the 2nd quarter valued at approximately $157,000. Entropy Technologies LP acquired a new position in shares of NeuroPace in the 3rd quarter valued at approximately $146,000. Diversified Trust Co bought a new stake in shares of NeuroPace during the 3rd quarter worth approximately $153,000. Finally, Bank of America Corp DE bought a new stake in shares of NeuroPace during the 2nd quarter worth approximately $322,000. Institutional investors own 78.83% of the company’s stock.
About NeuroPace
NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.
Further Reading
- Five stocks we like better than NeuroPace
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.
